Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122


Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.

Rahimov F, King OD, Warsing LC, Powell RE, Emerson CP Jr, Kunkel LM, Wagner KR.

Physiol Genomics. 2011 Apr 27;43(8):398-407. doi: 10.1152/physiolgenomics.00223.2010. Epub 2011 Jan 25.


Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice.

Allen DL, Cleary AS, Speaker KJ, Lindsay SF, Uyenishi J, Reed JM, Madden MC, Mehan RS.

Am J Physiol Endocrinol Metab. 2008 May;294(5):E918-27. doi: 10.1152/ajpendo.00798.2007. Epub 2008 Mar 11.


Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.

Chiu CS, Peekhaus N, Weber H, Adamski S, Murray EM, Zhang HZ, Zhao JZ, Ernst R, Lineberger J, Huang L, Hampton R, Arnold BA, Vitelli S, Hamuro L, Wang WR, Wei N, Dillon GM, Miao J, Alves SE, Glantschnig H, Wang F, Wilkinson HA.

J Gerontol A Biol Sci Med Sci. 2013 Oct;68(10):1181-92. doi: 10.1093/gerona/glt030. Epub 2013 Mar 22.


A myostatin and activin decoy receptor enhances bone formation in mice.

Bialek P, Parkington J, Li X, Gavin D, Wallace C, Zhang J, Root A, Yan G, Warner L, Seeherman HJ, Yaworsky PJ.

Bone. 2014 Mar;60:162-71. doi: 10.1016/j.bone.2013.12.002. Epub 2013 Dec 9.


The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.

O'Connell KE, Guo W, Serra C, Beck M, Wachtman L, Hoggatt A, Xia D, Pearson C, Knight H, O'Connell M, Miller AD, Westmoreland SV, Bhasin S.

FASEB J. 2015 Apr;29(4):1165-75. doi: 10.1096/fj.14-257543. Epub 2014 Dec 2.


Elevated expression of activins promotes muscle wasting and cachexia.

Chen JL, Walton KL, Winbanks CE, Murphy KT, Thomson RE, Makanji Y, Qian H, Lynch GS, Harrison CA, Gregorevic P.

FASEB J. 2014 Apr;28(4):1711-23. doi: 10.1096/fj.13-245894. Epub 2013 Dec 30.


Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures.

Kornegay JN, Bogan DJ, Bogan JR, Dow JL, Wang J, Fan Z, Liu N, Warsing LC, Grange RW, Ahn M, Balog-Alvarez CJ, Cotten SW, Willis MS, Brinkmeyer-Langford C, Zhu H, Palandra J, Morris CA, Styner MA, Wagner KR.

Skelet Muscle. 2016 Apr 4;6:14. doi: 10.1186/s13395-016-0085-7. eCollection 2016.


A novel therapeutic approach to treating obesity through modulation of TGFβ signaling.

Koncarevic A, Kajimura S, Cornwall-Brady M, Andreucci A, Pullen A, Sako D, Kumar R, Grinberg AV, Liharska K, Ucran JA, Howard E, Spiegelman BM, Seehra J, Lachey J.

Endocrinology. 2012 Jul;153(7):3133-46. doi: 10.1210/en.2012-1016. Epub 2012 May 1.


Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.

Kainulainen H, Papaioannou KG, Silvennoinen M, Autio R, Saarela J, Oliveira BM, Nyqvist M, Pasternack A, 't Hoen PA, Kujala UM, Ritvos O, Hulmi JJ.

Mol Cell Endocrinol. 2015 Jan 5;399:131-42. doi: 10.1016/j.mce.2014.10.001. Epub 2014 Oct 7.


The role of myostatin and activin receptor IIB in the regulation of unloading-induced myofiber type-specific skeletal muscle atrophy.

Babcock LW, Knoblauch M, Clarke MS.

J Appl Physiol (1985). 2015 Sep 15;119(6):633-42. doi: 10.1152/japplphysiol.00762.2014. Epub 2015 Jul 23.


Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.

Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Pasternack A, Kainulainen H, Ritvos O.

Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E171-82. doi: 10.1152/ajpendo.00065.2013. Epub 2013 May 21.


Development of novel activin-targeted therapeutics.

Chen JL, Walton KL, Al-Musawi SL, Kelly EK, Qian H, La M, Lu L, Lovrecz G, Ziemann M, Lazarus R, El-Osta A, Gregorevic P, Harrison CA.

Mol Ther. 2015 Mar;23(3):434-44. doi: 10.1038/mt.2014.221. Epub 2014 Nov 17.


Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice.

Sumner CJ, Wee CD, Warsing LC, Choe DW, Ng AS, Lutz C, Wagner KR.

Hum Mol Genet. 2009 Sep 1;18(17):3145-52. doi: 10.1093/hmg/ddp253. Epub 2009 May 28.


Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.

Puolakkainen T, Ma H, Kainulainen H, Pasternack A, Rantalainen T, Ritvos O, Heikinheimo K, Hulmi JJ, Kiviranta R.

BMC Musculoskelet Disord. 2017 Jan 19;18(1):20. doi: 10.1186/s12891-016-1366-3.


Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.

Liu M, Hammers DW, Barton ER, Sweeney HL.

PLoS One. 2016 Nov 21;11(11):e0166803. doi: 10.1371/journal.pone.0166803. eCollection 2016.


Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction.

Pistilli EE, Bogdanovich S, Mosqueira M, Lachey J, Seehra J, Khurana TS.

Am J Physiol Regul Integr Comp Physiol. 2010 Jan;298(1):R96-R103. doi: 10.1152/ajpregu.00138.2009. Epub 2009 Oct 28.


A soluble activin receptor type IIB does not improve blood glucose in streptozotocin-treated mice.

Wang Q, Guo T, Portas J, McPherron AC.

Int J Biol Sci. 2015 Jan 5;11(2):199-208. doi: 10.7150/ijbs.10430. eCollection 2015.


A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.

Morrison BM, Lachey JL, Warsing LC, Ting BL, Pullen AE, Underwood KW, Kumar R, Sako D, Grinberg A, Wong V, Colantuoni E, Seehra JS, Wagner KR.

Exp Neurol. 2009 Jun;217(2):258-68. doi: 10.1016/j.expneurol.2009.02.017. Epub 2009 Mar 11.


Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.

Souza TA, Chen X, Guo Y, Sava P, Zhang J, Hill JJ, Yaworsky PJ, Qiu Y.

Mol Endocrinol. 2008 Dec;22(12):2689-702. doi: 10.1210/me.2008-0290. Epub 2008 Oct 16.

Supplemental Content

Support Center